PX-GDE-26 · GCP · GLP · Commercialization
Scaling from clinical trials to commercialization: GCP and GLP on ServiceNow.
Clinical-stage biotechs advancing from Phase II and III into commercial launch face an abrupt jump in ICH E6(R3) computerized-system governance, CRO and eTMF oversight, GLP laboratory change control, and pre-approval inspection scrutiny—without years to build a validation bureaucracy. ProcessX by USDM Life Sciences deploys pre-configured, validated workflows on ServiceNow in 6–12 weeks, establishing 21 CFR Part 11 readiness with embedded USDM engineers.
- INFLECTION POINTPAI audit riskMoving from clinical development to NDA or BLA submission exposes ad-hoc spreadsheets across EDC, eTMF, LIMS, and CROs
- ICH E6(R3)Sponsor-owned evidenceSponsor data-governance duties cover clinical computerized systems, role-based access, audit-trail review, and service-provider oversight
- GLP & QC LABS21 CFR Part 58LIMS, CDS, bioanalytical instruments, and assay software follow governed applicability, change, incident, and calibration workflows
- FAST DEPLOYMENT6–12 weeks livePre-validated ProcessX workflows deploy with embedded USDM engineers in 6–12 weeks without hiring a large internal CSV team
- PROVEN PATHCommercial launch readyArrowhead Pharmaceuticals used ProcessX pre-configured workflows and Part 11 controls to move onto ServiceNow ready for commercialization
Why Phase II spreadsheet governance breaks ahead of BLA and NDA inspections.
In early clinical development, lean biotech IT and Quality teams often track system inventories, CRO oversight, and laboratory software changes in shared spreadsheets and email approvals. As pivotal Phase III readouts approach and NDA or BLA submissions begin, regulatory expectations steepen overnight. ICH E6(R3) places explicit computerized-system data governance onto the sponsor—requiring documented fitness for intended use, role-segregated access, periodic audit-trail evaluations, and active oversight of CRO-hosted EDC, IRT, eCOA, and eTMF platforms.
At the same moment, bioanalytical and GLP study laboratories operating under 21 CFR Part 58 are joined by commercial ERP, LIMS, Chromatography Data Systems (CDS), and external CDMO supply chains preparing for Pre-Approval Inspection (PAI). Trying to invent custom ServiceNow forms and write validation scripts from scratch during launch preparation slows IT down just when every clinical, laboratory, and commercial system onboarded is on the critical path.
Sponsor blind spots on CRO-managed clinical platforms (ICH E6(R3))
Delegating EDC, IRT, or eCOA administration to a CRO without sponsor-controlled qualification records, access governance, and edit-check change oversight leaves the sponsor exposed during GCP BIMO inspections.
Ad-hoc GLP and bioanalytical laboratory changes (21 CFR Part 58)
LIMS configuration updates, CDS method templates, and analytical instrument firmware upgrades applied via informal lab tickets break study reconstruction and raw-data integrity.
Unverified user access across clinical, medical, and QC roles (Annex 11 §12)
Rapid pre-commercial hiring and external contractor turnover outpace manual access spreadsheets, allowing unblinded or untrained permissions to linger on regulated SaaS systems.
Building a bespoke CSV machine instead of launching
Authoring custom Part 11 controls and document-heavy validation binders internally consumes quarters of engineering and Quality capacity right before commercial readiness deadlines.
Deploying GCP, GLP, vendor, and IT governance on ServiceNow in 6–12 weeks.
ProcessX by USDM Life Sciences gives clinical-stage and commercializing companies a validated scoped application on ServiceNow—complete with hash-chained 21 CFR Part 11 and EU Annex 11 electronic signatures, immutable audit trails, and pre-built workflows for system applicability, validated change, GxP incidents, CMDB/CSDM inventory, training-gated access, periodic and audit-trail reviews, and CRO/vendor qualification. Embedded USDM engineers configure and validate the first production workflows with your team in 6–12 weeks.
Arrowhead Pharmaceuticals followed this exact path onto ServiceNow, using ProcessX pre-configured workflows, Part 11 approvals, and validation to meet its regulatory obligations without building a sprawling internal validation machine—an outcome Gabe Peterson, VP, Information Systems & Informatics at Arrowhead Pharmaceuticals, described as a major step forward in getting onto ServiceNow and ready for commercialization. Similarly, in anonymized clinical-stage oncology deployments, aligning regulated IT workflows and CSDM system ownership on ProcessX replaced fragmented trackers with one audit-ready platform.
- SYSTEM SCOPERegulatory applicability assessments classify every EDC, eTMF, LIMS, CDS, ERP, and SaaS tool once across GCP, GLP, and GMP data criticalityDocumented scope
- CRO & SAAS RISKQualifies CROs, central labs, and clinical SaaS platforms with linked Quality Agreements, SaaS release impact checks, and AI boundary conditionsSponsor oversight
- LAB & IT CHANGERoutes LIMS, CDS, instrument, and clinical system changes by risk under FDA CSA—binding verification evidence and DMS SOP readiness prior to releaseCSA-aligned change
- BLINDED ACCESSEnforces LMS training verification before provisioning regulated system roles and runs signed periodic user-access and audit-trail reviewsTraining & role gated
- RELEASE READYProcessX arrives validated on every release so your lean Quality team approves intended use rather than maintaining custom compliance codeValidated foundation
Example · GLP / QC LIMS release and audit-trail review readiness on ServiceNow
An illustrative pre-commercial LIMS configuration change governed in ProcessX: GCP/GLP/GMP applicability is linked on the CMDB asset, CSA intended-use testing and LMS training are verified, and Quality signs production release.
Re-authenticated Part 11 Quality Assurance e-signature releasing configuration to production
Inspection only. The example record and its signature state stay unchanged.Keeping clinical, laboratory, and commercial systems in a validated state.
Commercial approval is the beginning of recurring regulatory maintenance, not the finish line. Because ProcessX runs GCP, GLP, and GMP workflows on one scoped ServiceNow foundation, biotechs do not have to rip and replace clinical trackers at launch—they extend the same governed record graph into CDMO supplier quality, deviations, compliant post-market intake, and optional governed AI when ready, backed by USDM managed operations and upgrade regression.
Clinical, laboratory, and launch controls inside ProcessX
- C1Mandatory GxP applicability and risk-tier determinations for every internal and CRO-hosted clinical, lab, and commercial system
- C2Role-segregated Part 11 electronic signatures separating IT/informatics execution, study or lab system owners, and Quality Assurance
- C3Training-gated access provisioning and scheduled access reviews protecting blinded clinical roles and GLP/GMP data integrity
- C4Pre-approved GxP standard change templates so routine low-risk lab and clinical updates move fast without bypassing governance
Inspection-ready BIMO, GLP, and PAI evidence on ServiceNow
- E1Live CMDB/CSDM register of validated clinical, laboratory, and commercial systems with owners, risk tiers, and vendor links
- E2Signed ICH E6(R3) and Annex 11 §9 periodic and audit-trail review records with documented scope and exception outcomes
- E3Traceable CSA verification, change history, and incident impact evaluations bound directly to each regulated system record
- E4ProcessX release validation packages plus signed ServiceNow upgrade regression summaries keeping the platform continuously inspection-ready
Questions teams ask during validation and inspection
How does ProcessX help clinical-stage sponsors meet ICH E6(R3) computerized-system expectations?
ICH E6(R3) requires sponsors to maintain risk-proportionate governance over clinical computerized systems—including fitness for intended use, role-based access control, periodic audit-trail review, incident management, and oversight of CRO-provided tools. ProcessX turns each of those sponsor responsibilities into structured, Part 11 signed workflows on ServiceNow rather than scattered CRO email threads and static spreadsheets.
Can a lean biotech deploy ProcessX on ServiceNow without a large internal CSV team?
Yes. ProcessX arrives pre-validated on every release with 21 CFR Part 11 controls and pre-built regulated workflows, and embedded USDM engineers configure and validate your first production workflows alongside your team in 6–12 weeks. As Arrowhead Pharmaceuticals demonstrated ahead of commercialization, that model lets fast-growing companies establish audit-ready ServiceNow governance without building an internal validation bureaucracy.
How does ProcessX govern GLP laboratory instruments and LIMS changes alongside IT systems?
ProcessX registers LIMS, Chromatography Data Systems, bioanalytical software, and connected instruments as governed configuration items in ServiceNow with documented 21 CFR Part 58 or GMP applicability. Changes, incidents, user-access requests, and periodic reviews on laboratory systems follow risk-scaled CSA workflows that enforce analyst training checks and independent Quality sign-off.
What happens to our GCP and GLP ServiceNow workflows once our first commercial product launches?
Your team stays on the same validated ServiceNow foundation and adds GMP commercial workflows—such as ERP and CDMO change governance, deviations and product holds, and compliant post-market complaint and vigilance intake—without standing up a second compliance platform. Under managed operations, USDM can also run automated ServiceNow upgrade regression on your validation instance so commercial velocity never stalls.
Workflow products that enforce these controls
Pre-built starting points configured and validated on your ServiceNow instance by USDM engineers.
- Validated stateApplicability assessment, periodic and audit trail review, GxP standard change, and an app validated on every release.
- GxP third-party riskRisk-tiered vendor intake, AI vendor assessment, qualification and quality agreements, and SaaS release and re-assessment workflows.
- Regulated ITSMValidated change, GxP incident, CMDB/CSDM governance, and training-gated access and review — governed and evidenced.
Related technical guides.
- CDMO · CRO · Supplier QualityGoverning CDMO, CRO, and critical GxP supplier quality on ServiceNow
- Paperless CSA · TraceabilityPaperless CSA validation and live requirements-to-release traceability on ServiceNow
- GxP Scoping · Risk TieringAutomating GxP regulatory applicability and system risk scoping on ServiceNow
- Part 11 · Annex 1121 CFR Part 11 and EU Annex 11 controls on ServiceNow
- Full libraryBrowse all 26 technical guides by topic cluster
Prepare your ServiceNow for GCP, GLP, and commercial readiness.
Scaling toward pivotal trials, BLA/NDA submission, or commercial launch? Bring your clinical, laboratory, and vendor system list and we will map a 6–12 week rollout inside ServiceNow.
or email processx@usdm.com